CAS: 1446790-62-0
| Brand | Product data | Purity | Price range | Estimated delivery |
|---|---|---|---|---|
 | RO9021 REF: IN-DA00ABT7CAS: 1446790-62-0 | 99% | To inquire | Tue 19 Nov 24 |
 | RO9021 REF: 3D-WHC79062CAS: 1446790-62-0 | Min. 95% | To inquire | Thu 02 Jan 25 |
 | RO9021 REF: TM-T16776CAS: 1446790-62-0 | 97.19% | 51.00 €~1,813.00 € | Tue 07 Jan 25 |
Ref: IN-DA00ABT7
| 1mg | 168.00 € | ||
| 5mg | 613.00 € | ||
| 25mg | To inquire |
Estimated delivery in United States, on Tuesday 19 Nov 2024
RO9021
CAS:1446790-62-0
RO9021 is a novel, orally bioavailable, small-molecule CDK4/6 inhibitor that blocks the cell cycle at …
Formula:
C18H25N7O
Purity:
Min. 95%
Molecular weight:
355.44 g/mol
Ref: 3D-WHC79062
| 1mg | To inquire | ||
| 5mg | To inquire | ||
| 10mg | To inquire | ||
| 25mg | To inquire | ||
| 50mg | To inquire |
Estimated delivery in United States, on Thursday 2 Jan 2025
RO9021
CAS:1446790-62-0
RO9021 is an orally bioavailable, novel ATP-competitive SYK inhibitor (average IC50: 5.6 nM).
Formula:
C18H25N7O
Purity:
97.19%
Color and Shape:
Solid
Molecular weight:
355.44
Ref: TM-T16776
| 1mg | 51.00 € | ||
| 5mg | 113.00 € | ||
| 10mg | 171.00 € | ||
| 25mg | 274.00 € | ||
| 50mg | 399.00 € | ||
| 100mg | 542.00 € | ||
| 200mg | 729.00 € |
Estimated delivery in United States, on Tuesday 7 Jan 2025
